IMETABOLIC BIOPHARMA CORPORATION

Biotech · Private

iMBP-001, a dual-domain therapeutic peptide combining ApoC-III antagonist and ApoE mimetic domains to target and clear small dense LDL particles in cardiovascular disease.

Grants
$583K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation$283,123
Federal grantDepartment of Health and Human Services · Phase I · Therapeutic Approach to Clear sdLDL from Circulation$299,504
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3203NAJIT TECHNOLOGIES, INC.——
3204OM THERAPEUTICS INC.——
3205Anaveon——
3206IMETABOLIC BIOPHARMA CORPORATION——
3207AcePre, LLC——
3208CuronBiotech Inc——
3209Gerologix, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.